“We were delighted to work with Scius who collaboratively supported us as we announced our venture debt financing from the European Investment Bank. The coverage we received did a great job in highlighting the news and the capabilities of ExeVir in general including the potential of the company’s llama derived antibodies for protecting immunocompromised patients from COVID19.”

Torsten Mummenbrauer, CEO of ExeVir Bio